Abstract
QUESTION: I have an 8-weeks' pregnant patient who was diagnosed with stage III Hodgkin's disease last week. The oncologist suggests delaying chemotherapy until the second trimester. What are the effects of chemotherapy on a fetus after the first trimester? Where can I find reliable information on the subject? ANSWER: Available data suggest that exposure to chemotherapy during the first trimester of pregnancy is associated with increased risk of major malformations. Exposure during the second and third trimesters does not result in major malformations, but could have nonteratogenic effects, such as low birth weight. The brain develops throughout pregnancy, and it could be affected later in pregnancy.
Full Text
The Full Text of this article is available as a PDF (52.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Antonelli N. M., Dotters D. J., Katz V. L., Kuller J. A. Cancer in pregnancy: a review of the literature. Part I. Obstet Gynecol Surv. 1996 Feb;51(2):125–134. doi: 10.1097/00006254-199602000-00022. [DOI] [PubMed] [Google Scholar]
- Avilés A., Díaz-Maqueo J. C., Talavera A., Guzmán R., García E. L. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol. 1991 Apr;36(4):243–248. doi: 10.1002/ajh.2830360404. [DOI] [PubMed] [Google Scholar]
- Berry D. L., Theriault R. L., Holmes F. A., Parisi V. M., Booser D. J., Singletary S. E., Buzdar A. U., Hortobagyi G. N. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999 Mar;17(3):855–861. doi: 10.1200/JCO.1999.17.3.855. [DOI] [PubMed] [Google Scholar]
- Blatt J., Mulvihill J. J., Ziegler J. L., Young R. C., Poplack D. G. Pregnancy outcome following cancer chemotherapy. Am J Med. 1980 Dec;69(6):828–832. doi: 10.1016/s0002-9343(80)80007-6. [DOI] [PubMed] [Google Scholar]
- Doll D. C., Ringenberg Q. S., Yarbro J. W. Management of cancer during pregnancy. Arch Intern Med. 1988 Sep;148(9):2058–2064. [PubMed] [Google Scholar]
- Ebert U., Löffler H., Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997;74(2):207–220. doi: 10.1016/s0163-7258(97)82004-9. [DOI] [PubMed] [Google Scholar]
- Egan P. C., Costanza M. E., Dodion P., Egorin M. J., Bachur N. R. Doxorubicin and cisplatin excretion into human milk. Cancer Treat Rep. 1985 Dec;69(12):1387–1389. [PubMed] [Google Scholar]
- Koren G., Weiner L., Lishner M., Zemelickes D., Finegen J. Cancer in pregnancy: identification of unanswered questions on maternal and fetal risks. Obstet Gynecol Surv. 1990 Aug;45(8):509–514. [PubMed] [Google Scholar]
- Nicholson H. O. Cytotoxic drugs in pregnancy. Review of reported cases. J Obstet Gynaecol Br Commonw. 1968 Mar;75(3):307–312. doi: 10.1111/j.1471-0528.1968.tb02083.x. [DOI] [PubMed] [Google Scholar]
- SOKAL J. E., LESSMANN E. M. Effects of cancer chemotherapeutic agents on the human fetus. J Am Med Assoc. 1960 Apr 16;172:1765–1771. doi: 10.1001/jama.1960.63020160002008. [DOI] [PubMed] [Google Scholar]
- Sutcliffe S. B. Treatment of neoplastic disease during pregnancy: maternal and fetal effects. Clin Invest Med. 1985;8(4):333–338. [PubMed] [Google Scholar]
- Zemlickis D., Lishner M., Degendorfer P., Panzarella T., Sutcliffe S. B., Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med. 1992 Mar;152(3):573–576. [PubMed] [Google Scholar]
- Zemlickis D., Lishner M., Erlich R., Koren G. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen. 1993;13(3):139–143. doi: 10.1002/tcm.1770130304. [DOI] [PubMed] [Google Scholar]
- de Vries E. G., van der Zee A. G., Uges D. R., Sleijfer D. T. Excretion of platinum into breast milk. Lancet. 1989 Mar 4;1(8636):497–497. doi: 10.1016/s0140-6736(89)91396-2. [DOI] [PubMed] [Google Scholar]